玻璃体腔注射阿柏西普治疗息肉状脉络膜血管病变的PLANET研究
这项96周、双盲、假注射对照的3b/4期随机临床试验在多个国家纳入318例症状性黄斑息肉状脉络膜血管病变成人患者,比较阿柏西普单药与阿柏西普联合补救性光动力疗法的疗效与安全性。结果显示阿柏西普单药在52周最佳矫正视力平均变化方面非劣于联合组(+10.7 vs +10.8字母,95%CI -2.9至1.6,P=.55),需补救治疗者较少(12.1% vs 14.3%)。作者认为超过85%接受单药治疗的参与者获得视觉和/或功能结局改善。
要点
- 阿柏西普单药在52周视力平均变化上非劣于阿柏西普联合补救性光动力疗法。
- 单药组与联合组分别有12.1%和14.3%的参与者需要补救治疗。
- 超过85%接受阿柏西普单药治疗的参与者获得视觉和/或功能结局改善。
核心结论
- 阿柏西普单药治疗在52周最佳矫正视力平均变化方面非劣于阿柏西普联合补救性光动力疗法(+10.7 vs +10.8字母,95%CI -2.9至1.6,P=.55)。
- 超过85%接受阿柏西普单药治疗的参与者获得视觉和/或功能结局改善,超过80%的参与者息肉状病灶无渗漏征象。
- 由于少于15%的参与者符合对光动力疗法反应不佳的标准而接受光动力疗法,加用光动力疗法的潜在获益无法确定。
研究设计与样本
- 这是一项96周、双盲、假注射对照的3b/4期随机临床试验,在澳大利亚、德国、香港、匈牙利、日本、新加坡、韩国和台湾的多个中心进行,时间为2014年5月至2016年8月。
- 纳入标准为50岁及以上、有症状性黄斑息肉状脉络膜血管病变、最佳矫正视力为73至24个早期治疗糖尿病视网膜病变研究字母(相当于Snellen 20/40-20/320)的成人。
- 共纳入318例参与者,平均(SD)年龄70.6(8.2)岁,女性96例(30.2%),日本裔152例(47.8%)。
主要发现
- 第0、4、8周给予2 mg阿柏西普玻璃体腔注射;第12周时对反应不佳的参与者按1:1随机分配接受阿柏西普单药加假光动力疗法或阿柏西普加补救性光动力疗法。
- 主要终点第52周最佳矫正视力较基线的平均变化:阿柏西普单药组+10.7字母 vs 阿柏西普联合光动力疗法组+10.8字母(95%CI -2.9至1.6,P=.55)。
- 需要补救治疗的参与者分别为19例(12.1%)和23例(14.3%)。
- 第52周黄斑中心凹亚区厚度较基线平均变化:阿柏西普单药组-137.7 μm vs 阿柏西普联合光动力疗法组-143.5 μm。
- 第52周吲哚菁绿血管造影未见息肉状病灶者分别为49例(38.9%)和60例(44.8%),无息肉状病灶伴渗漏者分别为116例(81.7%)和136例(88.9%)。
关键数值与推荐
- 主要终点为非劣效性:阿柏西普单药组与阿柏西普联合光动力疗法组第52周最佳矫正视力平均变化差值的95%CI完全高于-5字母。
- 最常见眼部不良事件:阿柏西普单药组为结膜出血8例(5.1%),阿柏西普联合光动力疗法组为干眼9例(5.6%)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 由于少于15%的参与者符合对光动力疗法反应不佳的标准而接受光动力疗法,加用光动力疗法的潜在获益无法确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Polypoidal choroidal vasculopathy (PCV) is common in Asian populations, but an optimal treatment approach remains to be confirmed. OBJECTIVE: To evaluate intravitreal aflibercept injection (IAI) in participants with PCV and compare IAI monotherapy with IAI plus rescue photodynamic therapy (PDT). DESIGN, SETTING, AND PARTICIPANTS: This 96-week, double-masked, sham-controlled phase 3b/4 randomized clinical trial was conducted at multiple centers in Australia, Germany, Hong Kong, Hungary, Japan, Singapore, South Korea, and Taiwan from May 2014 to August 2016, and included adults 50 years or older with symptomatic macular PCV and a best-corrected visual acuity of 73 to 24 Early Treatment Diabetic Retinopathy Study letters (20/40-20/320 Snellen equivalent). INTERVENTIONS: Participants received 2 mg of IAI at weeks 0, 4, and 8. At week 12, participants with a suboptimal response were randomized 1:1 to receive IAI plus sham PDT (IAI monotherapy) or a "rescue" of IAI plus rescue PDT (IAI/PDT). Participants who did not qualify for rescue received IAI every 8 weeks; those qualifying for rescue received IAI every 4 weeks plus sham/active PDT. When the rescue criteria were no longer met, injection intervals were gradually extended to 8 weeks. MAIN OUTCOMES AND MEASURES: Noninferiority of IAI monotherapy to IAI/PDT for mean change in best-corrected visual acuity from baseline to week 52 (95% CI of the difference entirely above -5 letters). RESULTS: Of the 318 participants, the mean (SD) age was 70.6 (8.2) years, 96 (30.2%) were women, and 152 (47.8%) were Japanese. Monotherapy with IAI was noninferior to IAI/PDT for the primary end point (+10.7 vs +10.8 letters, respectively; 95% CI, -2.9 to 1.6; P = .55), with few participants requiring rescue therapy (19 [12.1%] vs 23 [14.3%], respectively). Participants in both treatment groups had similar reductions in central subfield thickness from baseline to week 52 (-137.7 [IAI monotherapy] vs -143.5 μm [IAI/PDT]). At week 52, 49 (38.9%) and 60 participants (44.8%) had no polypoidal lesions observed on indocyanine green angiography in the IAI monotherapy and IAI/PDT groups, respectively. Furthermore, 116 (81.7%) and 136 (88.9%), respectively, had no polypoidal lesions with leakage. The most frequent ocular adverse events were conjunctival hemorrhage (IAI monotherapy, 8 [5.1%]) and dry eye (IAI/PDT, 9 [5.6%]). CONCLUSIONS AND RELEVANCE: Improvement in visual and/or functional outcomes was achieved in more than 85% of participants who were treated with IAI monotherapy, with no signs of leakage from polypoidal lesions in more than 80%. As fewer than 15% met the criteria of a suboptimal response to receive PDT, the potential benefit of adding PDT cannot be determined. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02120950.
引用
- Lee WK, Iida T, Ogura Y, et al. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018. PMID: 29801063. doi:10.1001/jamaophthalmol.2018.1804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。